QQQ   418.99 (-1.04%)
AAPL   165.24 (-1.08%)
MSFT   402.14 (-0.53%)
META   488.94 (-2.56%)
GOOGL   154.88 (-0.72%)
AMZN   176.24 (-1.66%)
TSLA   149.67 (-0.17%)
NVDA   823.50 (-2.74%)
AMD   150.42 (-3.00%)
NIO   3.86 (-3.50%)
BABA   68.88 (+0.00%)
T   16.28 (-0.31%)
F   12.12 (+0.50%)
MU   108.10 (-3.42%)
GE   150.83 (-1.38%)
CGC   7.78 (-0.64%)
DIS   111.89 (-0.48%)
AMC   3.10 (+6.16%)
PFE   25.73 (+1.34%)
PYPL   62.09 (-0.02%)
XOM   120.18 (+1.40%)
QQQ   418.99 (-1.04%)
AAPL   165.24 (-1.08%)
MSFT   402.14 (-0.53%)
META   488.94 (-2.56%)
GOOGL   154.88 (-0.72%)
AMZN   176.24 (-1.66%)
TSLA   149.67 (-0.17%)
NVDA   823.50 (-2.74%)
AMD   150.42 (-3.00%)
NIO   3.86 (-3.50%)
BABA   68.88 (+0.00%)
T   16.28 (-0.31%)
F   12.12 (+0.50%)
MU   108.10 (-3.42%)
GE   150.83 (-1.38%)
CGC   7.78 (-0.64%)
DIS   111.89 (-0.48%)
AMC   3.10 (+6.16%)
PFE   25.73 (+1.34%)
PYPL   62.09 (-0.02%)
XOM   120.18 (+1.40%)
QQQ   418.99 (-1.04%)
AAPL   165.24 (-1.08%)
MSFT   402.14 (-0.53%)
META   488.94 (-2.56%)
GOOGL   154.88 (-0.72%)
AMZN   176.24 (-1.66%)
TSLA   149.67 (-0.17%)
NVDA   823.50 (-2.74%)
AMD   150.42 (-3.00%)
NIO   3.86 (-3.50%)
BABA   68.88 (+0.00%)
T   16.28 (-0.31%)
F   12.12 (+0.50%)
MU   108.10 (-3.42%)
GE   150.83 (-1.38%)
CGC   7.78 (-0.64%)
DIS   111.89 (-0.48%)
AMC   3.10 (+6.16%)
PFE   25.73 (+1.34%)
PYPL   62.09 (-0.02%)
XOM   120.18 (+1.40%)
QQQ   418.99 (-1.04%)
AAPL   165.24 (-1.08%)
MSFT   402.14 (-0.53%)
META   488.94 (-2.56%)
GOOGL   154.88 (-0.72%)
AMZN   176.24 (-1.66%)
TSLA   149.67 (-0.17%)
NVDA   823.50 (-2.74%)
AMD   150.42 (-3.00%)
NIO   3.86 (-3.50%)
BABA   68.88 (+0.00%)
T   16.28 (-0.31%)
F   12.12 (+0.50%)
MU   108.10 (-3.42%)
GE   150.83 (-1.38%)
CGC   7.78 (-0.64%)
DIS   111.89 (-0.48%)
AMC   3.10 (+6.16%)
PFE   25.73 (+1.34%)
PYPL   62.09 (-0.02%)
XOM   120.18 (+1.40%)
Free Trial
NASDAQ:ANCN

Anchiano Therapeutics (ANCN) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)
Free ANCN Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.62
▼
$0.70
50-Day Range
$2.82
▼
$59.00
52-Week Range
$0.51
▼
$10.55
Volume
29,723 shs
Average Volume
3.15 million shs
Market Capitalization
$5.19 million
P/E Ratio
4.67
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsSocial Media
ANCN stock logo

About Anchiano Therapeutics Stock (NASDAQ:ANCN)

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

ANCN Stock News Headlines

May 29, 2023 | finance.yahoo.com
Rakovina Therapeutics Inc. Announces 2022 Financial Results and Convertible Debenture Financing
May 27, 2023 | morningstar.com
ITeos Therapeutics Inc Ordinary Shares
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
May 20, 2023 | seekingalpha.com
ENDV Endonovo Therapeutics, Inc.
May 18, 2023 | msn.com
Looking Into Oncternal Therapeutics's Return On Capital Employed
May 18, 2023 | msn.com
Anticompetitive Behavior At United Therapeutics, Regeneron, And The FTC
May 16, 2023 | msn.com
FTC sues to block Amgen’s acquisition of Horizon Therapeutics
May 16, 2023 | msn.com
FTC sues to block Amgen acquisition of Horizon Therapeutics
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
May 12, 2023 | msn.com
Recap: Abeona Therapeutics Q1 Earnings
May 9, 2023 | msn.com
TScan Therapeutics More than Doubles Following Deal with Amgen
April 26, 2023 | benzinga.com
Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting
April 5, 2023 | finanznachrichten.de
Perspective Therapeutics, Inc.: Perspective Therapeutics Expands Management Team And Names Andrew Bright as Executive Vice-President of Brachytherapy
March 27, 2023 | news.yahoo.com
Cigna's PBM, two others sued in Ohio over drug price fixing - WSJ
February 25, 2023 | finanznachrichten.de
Defence Therapeutics Inc.: Defence Therapeutics and CQDM Fund the Development of a New Cancer Vaccine Platform
February 18, 2023 | benzinga.com
Voyager Therapeutics Stock (NASDAQ:VYGR), Quotes and News Summary
February 11, 2023 | yahoo.com
Molina Healthcare, Inc. (NYSE:MOH) Q4 2022 Earnings Call Transcript
February 10, 2023 | benzinga.com
Revance Therapeutics Stock (NASDAQ:RVNC), Quotes and News Summary
January 5, 2023 | markets.businessinsider.com
Jnana Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 29, 2022 | msn.com
Down -41.38% in 4 Weeks, Here's Why Allogene Therapeutics (ALLO) Looks Ripe for a Turnaround
December 27, 2022 | benzinga.com
Onconova Therapeutics's Return On Capital Employed Insights
December 13, 2022 | barrons.com
3 Reasons Amgen Is Buying Horizon — and Why It Wasn’t the Only Company Interested
December 13, 2022 | msn.com
Amgen to buy Horizon Therapeutics in $26.4 billion deal
December 12, 2022 | msn.com
Here's Where Amgen's Loan To Acquire Horizon Therapeutics For $28B Ranks Among M&A Deals In 2022
December 12, 2022 | markets.businessinsider.com
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc
December 12, 2022 | msn.com
Amgen secures $28.3 billion deal to buy Horizon Therapeutics
December 12, 2022 | msn.com
Amgen to Buy Horizon Therapeutics in $27.8 Billion Deal
See More Headlines
Receive ANCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anchiano Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/05/2019
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ANCN
CUSIP
N/A
CIK
N/A
Web
www.anchiano.com
Phone
857-259-4622
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($3.46)
Trailing P/E Ratio
4.67
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-27,120,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
36.08%
Return on Assets
27.40%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.25
Quick Ratio
3.25

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.01 per share
Price / Book
0.35

Miscellaneous

Outstanding Shares
7,420,000
Free Float
N/A
Market Cap
$5.19 million
Optionable
Not Optionable
Beta
0.93
Beginner's Guide to Pot Stock Investing Cover
Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Ronald K. Knickerbocker (Age 55)
    Sr. VP of Clinical Devel. & Data Sciences
    Comp: $352k
  • Mr. Neil H. Cohen (Age 58)
    CEO & Director
  • Prof. Abraham Hochberg (Age 83)
    Co-Founder & Chief Scientific Officer
  • Mr. Andrew Fine (Age 51)
    Chief Financial Officer
  • Mr. Avraham Hampel M.B.A.
    Deputy CFO & Company Sec.
  • Mr. Or Dolev (Age 43)
    Controller

Key Competitors

View All Competitors

ANCN Stock Analysis - Frequently Asked Questions

How were Anchiano Therapeutics' earnings last quarter?

Anchiano Therapeutics Ltd. (NASDAQ:ANCN) posted its earnings results on Monday, August, 5th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.12.

What other stocks do shareholders of Anchiano Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anchiano Therapeutics investors own include AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Abeona Therapeutics (ABEO), Achieve Life Sciences (ACHV), Acorda Therapeutics (ACOR), Acasti Pharma (ACST), Aduro Biotech (ADRO) and AnaptysBio (ANAB).

When did Anchiano Therapeutics IPO?

Anchiano Therapeutics (ANCN) raised $35 million in an initial public offering on Tuesday, February 12th 2019. The company issued 2,400,000 shares at $14.55 per share. Oppenheimer served as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

This page (NASDAQ:ANCN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research